MX2023007302A - Anticuerpos contra la integrina alfa 11 beta 1. - Google Patents

Anticuerpos contra la integrina alfa 11 beta 1.

Info

Publication number
MX2023007302A
MX2023007302A MX2023007302A MX2023007302A MX2023007302A MX 2023007302 A MX2023007302 A MX 2023007302A MX 2023007302 A MX2023007302 A MX 2023007302A MX 2023007302 A MX2023007302 A MX 2023007302A MX 2023007302 A MX2023007302 A MX 2023007302A
Authority
MX
Mexico
Prior art keywords
beta
integrin alpha
antibodies against
against integrin
antibodies
Prior art date
Application number
MX2023007302A
Other languages
English (en)
Inventor
Elma Kurtagic
Iii James W Meador
Christopher Beneduce
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Publication of MX2023007302A publication Critical patent/MX2023007302A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente descripción incluye anticuerpos que se unen específicamente a integrina alfa 11 beta 1 (a11ß1), así como a métodos para elaborar y usar tales anticuerpos.
MX2023007302A 2020-12-18 2021-12-17 Anticuerpos contra la integrina alfa 11 beta 1. MX2023007302A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063127849P 2020-12-18 2020-12-18
US202163213973P 2021-06-23 2021-06-23
PCT/IB2021/061926 WO2022130318A2 (en) 2020-12-18 2021-12-17 Antibodies against integrin alpha 11 beta 1

Publications (1)

Publication Number Publication Date
MX2023007302A true MX2023007302A (es) 2023-09-04

Family

ID=79021748

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023007302A MX2023007302A (es) 2020-12-18 2021-12-17 Anticuerpos contra la integrina alfa 11 beta 1.

Country Status (12)

Country Link
EP (1) EP4263605A2 (es)
JP (1) JP2024505790A (es)
KR (1) KR20230121831A (es)
AU (1) AU2021400221A1 (es)
BR (1) BR112023011777A2 (es)
CA (1) CA3205574A1 (es)
CL (1) CL2023001757A1 (es)
CO (1) CO2023008544A2 (es)
IL (1) IL303741A (es)
MX (1) MX2023007302A (es)
TW (1) TW202241946A (es)
WO (1) WO2022130318A2 (es)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE68013T1 (de) 1985-07-05 1991-10-15 Whitehead Biomedical Inst Expression von fremdem genetischem material in epithelzellen.
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
ATE117375T1 (de) 1987-09-11 1995-02-15 Whitehead Biomedical Inst Transduktionsveränderte fibroblasten und ihre anwendung.
DE3851153T2 (de) 1987-12-11 1995-01-05 Hughes Howard Med Inst Genetische modifizierung von endothelialen zellen.
DE68927996T2 (de) 1988-02-05 1997-12-04 Hughes Howard Med Inst Modifizierte hepatozyten und deren anwendung
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
ATE163046T1 (de) 1990-10-31 1998-02-15 Somatix Therapy Corp Genetische veränderung von endothelzellen
SE9201984D0 (sv) 1992-06-29 1992-06-29 Pharmacia Biosensor Ab Improvement in optical assays
US5308341A (en) 1993-09-28 1994-05-03 Becton, Dickinson And Company Method of testing the dose accuracy of a medication delivery device
US6146361A (en) 1996-09-26 2000-11-14 Becton Dickinson And Company Medication delivery pen having a 31 gauge needle
US6302855B1 (en) 1998-05-20 2001-10-16 Novo Nordisk A/S Medical apparatus for use by a patient for medical self treatment of diabetes
US6192891B1 (en) 1999-04-26 2001-02-27 Becton Dickinson And Company Integrated system including medication delivery pen, blood monitoring device, and lancer
US6277099B1 (en) 1999-08-06 2001-08-21 Becton, Dickinson And Company Medication delivery pen
DK1432466T3 (da) 2001-09-12 2012-12-03 Becton Dickinson Co Mikronål-baseret penapparat til lægemiddeludlevering og fremgangsmåde til anvendelse heraf
FR2849436B1 (fr) 2002-12-27 2007-01-05 Patrick Frayssinet Particules et ceramiques de phosphates de calcium pour transfection in vivo et in vitro
EP3524625A1 (en) * 2018-02-08 2019-08-14 Bergen Teknologioverforing AS Antibody against alpha-11 integrin and its use
PE20221723A1 (es) * 2019-12-20 2022-11-04 Momenta Pharmaceuticals Inc Anticuerpos contra la integrina alfa 11 beta 1

Also Published As

Publication number Publication date
BR112023011777A2 (pt) 2023-10-03
CA3205574A1 (en) 2022-06-23
WO2022130318A3 (en) 2022-08-04
TW202241946A (zh) 2022-11-01
EP4263605A2 (en) 2023-10-25
JP2024505790A (ja) 2024-02-08
KR20230121831A (ko) 2023-08-21
WO2022130318A2 (en) 2022-06-23
AU2021400221A1 (en) 2023-07-13
CL2023001757A1 (es) 2024-01-05
CO2023008544A2 (es) 2023-07-10
IL303741A (en) 2023-08-01

Similar Documents

Publication Publication Date Title
CA3156451A1 (en) ANTIBODIES WITH SPECIFICITY FOR NECTIN-4 AND THEIR USES
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
EP4248996A3 (en) Anti-trem2 antibodies and methods of use thereof
PH12020500671A1 (en) Antibodies specific for gucy2c and uses thereof
WO2019014328A3 (en) AGONISTIC ANTIBODIES THAT BIND HUMAN CD137 AND USES THEREOF
MX2016013970A (es) Conjugados anticuerpo-farmaco con carga alta de farmacos.
MX2020010951A (es) Anticuerpos anti-hla-g y utilizacion de los mismos.
MX2021006681A (es) Anticuerpos anti-claudina y usos de los mismos.
AU2018278321A1 (en) Chimeric antigen receptors targeting FLT3
MX2021002690A (es) Anticuerpos anti-avb8 y composiciones y usos de los mismos.
MX2021012692A (es) Anticuerpos anti-mertk y sus metodos de uso.
MY194603A (en) Anti-Complement Factor Bb Antibodies And Uses Thereof
MX2020010881A (es) Construcciones de anticuerpos anti-ror.
ZA202106602B (en) Claudin 6 antibodies and uses thereof
CR20200404A (es) Anticuerpos anti-klk5 y métodos de uso
MX2022003212A (es) Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecificos anti-klk5/klk7 y metodos de uso.
MX2022007231A (es) Anticuerpos anti-mertk y metodos de uso de los mismos.
MX2022005091A (es) Metodos de preparacion de una muestra enriquecida para la secuenciacion de polipeptidos.
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
MX2022007521A (es) Anticuerpos contra la integrina alfa 11 beta 1.
CR20230469A (es) Anticuerpos anti-nectina-4 y usos de los mismos
MX2021010254A (es) Conjugados de anticuerpo-farmaco que comprenden anticuerpos anti-tm4sf1 y metodos de uso de los mismos.
CR20230581A (es) Anticuerpos anti-CCR8 y usos de los mismos
MX2023001160A (es) Composicion farmaceutica del anticuerpo anti-pd-1 y uso del mismo.
MX2022003243A (es) Conjugados anticuerpo-farmaco anti-ptcra y usos de los mismos.